Fitness test for children and young adults with ITP
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This study looks at how fit children and young adults with ITP are. It involves a simple fitness test to help doctors understand your health better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 8 and 25 years old.
- You have been diagnosed with immune thrombocytopenic purpura (ITP), a bleeding disorder.
- Your doctor in the CEREVANCE network has referred you to an exercise lab as part of your routine care.
- You do not have any medical reasons that would make exercise unsafe for you.
- If you are under 18, your parent or guardian agrees to your participation.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an IV medicine called efgartigimod for teenagers (ages 12 to under 18) who have had chronic immune thrombocytopenia (ITP) for more than a year. The goal is to see if it can safely help raise platelet counts.
This trial studies whether a “dose-dense” rituximab schedule can help children and teens with newly diagnosed, high-risk immune thrombocytopenia (ITP). It aims to raise/maintain platelet counts and control bleeding, while carefully checking safety.
This trial looks at whether certain proteins in the blood can help doctors diagnose immune thrombocytopenia (ITP), a condition where your immune system destroys platelets. It may help find a faster, simpler way to confirm ITP.
This trial compares two ways to raise platelet counts in people with immune thrombocytopenia (ITP) who did not get enough benefit from a short course of a standard medicine. One option is a higher dose of a similar medicine, and the other is switching to a different pill. The goal is to find a treatment that works better with fewer side effects.
This trial studies whether “TPO” medicines (like eltrombopag or similar drugs) help people age 14 and older with primary immune thrombocytopenia (ITP) who did not respond well to first treatments. It may help raise platelet counts and reduce bleeding, especially when prior therapy hasn’t worked.
This trial tests an IV medicine called V-IMMUNE® for people with immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding. The study aims to see if V-IMMUNE® can safely raise platelet counts in both children and adults.
Hear when a new Immune Thrombocytopenic Purpura trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.